Eli Lilly (LLY) Gains from Investment Securities (2009 - 2026)

Eli Lilly has reported Gains from Investment Securities for 18 years, with the latest figure at $297.0 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities rose 367.57% year-over-year to $297.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 134.57% YoY), and the FY2025 full-year result was $645.0 million, down 4.73% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $297.0 million, down from $589.2 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $971.9 million in Q3 2023, with the low at -$456.8 million in Q2 2023.
• Historically, Gains from Investment Securities has averaged $173.5 million across 5 years, with a median of $151.9 million in 2024.
• Annual changes were most pronounced in 2022 — Gains from Investment Securities jumped 509.13% — and 2023, when it plunged 1966.97%.
• Eli Lilly's Gains from Investment Securities stood at $266.1 million in 2022, then slipped by 3.72% to $256.2 million in 2023, then tumbled by 40.71% to $151.9 million in 2024, then soared by 287.89% to $589.2 million in 2025, then sank by 49.59% to $297.0 million in 2026.
• The last three Gains from Investment Securities figures came in at $297.0 million (Q1 2026), $589.2 million (Q4 2025), and -$312.1 million (Q3 2025), per Business Quant data.